Uridina

Uridine

1. Identity: Chemical Names, Structure, and Physical Properties

Uridine (symbol U or Urd) is a glycosylated pyrimidine analog containing uracil attached to a ribose ring (or more specifically, a ribofuranose) via a β-N1-glycosidic bond. It is also known by the systematic IUPAC name 1-β-D-ribofuranosyluracil. Its chemical formula is C₉H₁₂N₂O₆, its molar mass is 244.20 g/mol, and it is a white, odorless crystalline powder.

Uridine is one of the five standard nucleosides that make up nucleic acids, the others being adenosine, thymidine, cytidine, and guanosine. Uridine is found in RNA and not DNA. Uridine is found in all living organisms as a structural component of RNA.

Of all the characterized and isolated pyrimidine natural products and natural product-derived compounds, uridine is the most abundant. Uridine is a pyrimidine nucleoside found in plasma and cerebrospinal fluid with a concentration higher than the other nucleosides.

Phosphorylated Forms and Related Compounds

When phosphate groups are added to uridine, a series of biologically critical nucleotides is produced:

• Uridine monophosphate (UMP) is a nucleoside phosphate comprised of a ribonucleoside and one phosphate group, with ribose as its sugar constituent.
• Uridine triphosphate (UTP) is a nucleoside phosphate comprised of a ribonucleoside and three phosphate groups, with ribose as its sugar constituent.
• Uridine diphosphate (UDP) and UDP-glucose are also key metabolic intermediates generated along the same biosynthetic pathway.

Common Supplemental Forms

Uridine is commercially available in several forms used in research and dietary supplementation:

• Free uridine — the unmodified nucleoside.
• Uridine-5′-monophosphate (UMP) — a phosphorylated form used in infant formula and studied in cognitive research.
• Triacetyluridine (TAU) — a prodrug form with substantially enhanced oral bioavailability. Product analysis of NucleomaxX® documented that more than 90% of the nucleoside component is in the form of triacetyluridine (TAU).
• Uridine triacetate (Xuriden®/Vistogard®) — an FDA-approved pharmaceutical form used for hereditary orotic aciduria and fluorouracil overdose.
• NucleomaxX® — a food supplement derived from sugar cane extract with a high nucleoside content used clinically in HIV-related mitochondrial toxicity studies. NucleomaxX® is a food supplement consisting of Mitocnol, an extract from sugar cane with a high content (17%) of nucleosides.

2. Natural Sources and Endogenous Biosynthesis

Dietary Sources

Some of the main dietary sources of uridine are RNA-enriched foods such as organ meats. It is found naturally in foods like brewer's yeast, organ meats, and certain vegetables. For infants, uridine is provided through breast milk and infant formulas, typically in the form of uridine monophosphate (UMP), which is bioavailable and absorbed through the digestive tract.

An important caveat regarding dietary intake exists: according to one study, uridine in the RNA form in food is not bioavailable. It is completely degraded by the gastrointestinal tract and the liver. This finding underscores why specific supplement forms designed for bioavailability — such as UMP or triacetyluridine — are used in clinical research contexts.

Endogenous Biosynthesis

Nucleosides such as uridine can be produced by de novo synthesis pathways. It is produced often as uridine monophosphate by the decarboxylation of orotidylate catalyzed by orotidylate decarboxylase. Pyrimidines are synthesized in the cytosol of various cell types including those of the spleen, thymus, and gastrointestinal tract. That process begins from the production of carbamoylphosphate. OMP is decarboxylated by the enzyme OMP decarboxylase to yield uridine monophosphate (UMP). Eventually, uridine diphosphate (UDP) and uridine triphosphate (UTP) are produced down the biosynthetic pathway by kinases and dephosphorylation of ATPs.

Plasma Concentrations and Bioavailability

Historically, the use of uridine as a therapeutic agent has been limited by poor bioavailability. In pharmacokinetic studies, baseline uridine concentrations were approximately 4.7–5.6 µM. NucleomaxX® contains more than 90% triacetyluridine (TAU), and single and repeated dosing resulted in peak plasma uridine concentrations of 150.9±39.3 µM and 161.4±31.5 µM, respectively, 1–2 hours after dosing — levels known to ameliorate mitochondrial toxicity in vitro. Drinking the contents of a single 36 g sachet of NucleomaxX® increases physiological serum concentration of uridine in humans from approximately 5 µM to more than 100 µM.

3. Historical and Traditional Use

Uridine as an isolated chemical entity has no pre-modern history of use in traditional medicine. It was identified and characterized as part of the broader scientific elucidation of nucleic acid biochemistry in the twentieth century. Pyrimidine nucleoside uridine is an essential natural nucleoside that is a key component of ribonucleic acid (RNA). This compound serves as a foundational precursor to numerous biological molecules and plays a crucial role in the pyrimidine metabolic pathway within the central nervous system.

The earliest documented therapeutic application of exogenous uridine is in the treatment of hereditary orotic aciduria, a rare inborn error of pyrimidine metabolism. Nineteen case reports of patients with hereditary orotic aciduria have been documented in published literature. Eighteen patients were diagnosed as infants or children between the ages of 2 months and 12 years and were treated with exogenous sources of uridine. These early clinical case records date to the late 1960s, with published accounts appearing from at least 1969, establishing uridine replacement as the standard of care for this condition well before modern dietary supplement use.

Interest in uridine as a broader nutritional supplement emerged in the late twentieth and early twenty-first centuries, driven primarily by laboratory findings regarding its role in brain membrane synthesis. Uridine in the form of UMP has been incorporated into specialized infant formulas due to its natural presence in breast milk and its role in infant neurodevelopment.

4. Key Constituents and Established Mechanisms of Action

4.1 The Kennedy Cycle and Membrane Phospholipid Synthesis

The most extensively characterized mechanism by which uridine exerts biological effects is through the Kennedy Cycle (CDP-choline pathway), the principal route of phosphatidylcholine (PC) synthesis in the brain.

All cells utilize DHA and other fatty acids, uridine, and choline to form phosphatidylcholine (PC) and other phosphatide subunits which, when aggregated, constitute the major components of their membranes. PC, the principal such subunit in brain, is synthesized from these precursors by the CDP-choline cycle or "Kennedy Cycle"; PC also provides the phosphocholine moiety needed to synthesize sphingomyelin (SM), the other major choline-containing brain phospholipid.

Plasma uridine crosses the blood-brain barrier and sequentially increases brain uridine, UTP, and CTP levels, as well as those of CDP-choline, the immediate precursor of PC. The CDP-choline then combines with a diacylglycerol (DAG), preferentially one containing a polyunsaturated fatty acid (PUFA) moiety such as DHA, to form PC.

Uridine is a precursor for the synthesis of CDP-choline, which is a key intermediate in the production of cell membrane phospholipids, particularly playing an indispensable role in the synthesis of phosphatidylcholine (lecithin). Phosphatidylcholine is one of the main components of the cell membrane, essential for maintaining the integrity and function of the cell membrane, and is required for the formation of neuronal cell membranes.

The phosphatide phosphatidylethanolamine (PE) is also synthesized via the Kennedy Cycle, utilizing ethanolamine instead of choline, while phosphatidylserine (PS), the third major structural phosphatide, is produced by exchanging a serine molecule for the choline in PC or the ethanolamine in PE.

4.2 UTP-Mediated P2Y Receptor Activation

The UTP formed in brain from uridine acts as a ligand to activate P2Y receptors that mediate neuronal differentiation and neurite outgrowth. The precursors act by enhancing the substrate saturation of enzymes that initiate their incorporation into phosphatidylcholine and phosphatidylethanolamine, and by UTP-mediated activation of P2Y receptors.

4.3 Synaptic Membrane and Synaptogenesis

Uridine supplementation not only increases protein O-GlcNAcylation, but also promotes synaptic membrane synthesis in the cerebral cortex and the hippocampus. Uridine is the substrate for synthesis of cytidine triphosphate, the nucleotide used for production of CDP-choline and CDP-ethanolamine. UMP pretreatment most likely affects dendritic spine formation in vivo by two mechanisms: by increasing CTP levels, it increases the formation of CDP-choline; and by increasing brain UTP, it activates metabotropic P2Y receptors.

4.4 Carbohydrate Metabolism and Galactose Utilization

Uridine plays a role in the glycolysis pathway of galactose. Once the incoming galactose has been converted into galactose 1-phosphate (Gal-1-P), it is involved in a reaction with UDP-glucose, a glucose molecule bonded to uridine diphosphate (UDP). This process is catalyzed by the enzyme galactose-1-phosphate uridyl transferase and transfers the UDP to the galactose molecule. The end result is UDP-galactose and glucose-1-phosphate.

In addition to nucleic acid synthesis, uridine is critical to glycogen synthesis through the formation of uridine diphosphate glucose, which promotes the production of UDP-GlcNAc in the hexosamine biosynthetic pathway and supplies UDP-GlcNAc for O-GlcNAcylation. This process can regulate protein modification and affect its function.

4.5 Circadian Rhythm and Metabolic Regulation

Uridine has an effect on body temperature and circadian rhythms, which can regulate the metabolic rate and the expression of metabolic genes. Abnormal levels of blood uridine have been found in people with diabetes and obesity, suggesting a link between uridine dysregulation and metabolic disorders.

4.6 Neuroprotection: Antioxidant and Anti-apoptotic Properties

Uridine enhances energy supply by enhancing mitochondrial function and protects neurons from metabolic stress. The neuroprotective effect of uridine was also correlated with reduced apoptosis. Overall, the neuroprotective effect of uridine is a multi-faceted, multi-level process involving multiple links, including antioxidant defense, immune regulation, energy metabolism and cellular repair, and anti-apoptosis.

Uridine was also able to mitigate morphine-induced conditioned place preference and to modulate glutamate/γ-aminobutyric acid levels in the mouse prefrontal cortex. Uridine can also have antiepileptic effects on seizures by regulating dopamine release and receptor expression.

4.7 Acetylcholine Synthesis

Cytidine and uridine can stimulate brain phosphatide synthesis without diminishing acetylcholine synthesis or release. The conversion of free choline to membrane phospholipids can be accelerated by uridine. Adding cytidine or uridine (both 25–400 µM) to media failed to affect acetylcholine release whether or not choline was also added, even though the pyrimidines (400 µM) did enhance choline's utilization to form CDP-choline by 89 or 61%, respectively. This finding indicates that uridine can upregulate membrane phospholipid synthesis without depleting the acetylcholine neurotransmitter pool.

5. Scientific Evidence by Area of Use

5.1 Hereditary Orotic Aciduria — Established Clinical Use

Overview: Uridine triacetate is used to treat hereditary orotic aciduria, a rare genetic disorder, and for the emergency treatment of overdose or toxicity from the treatment of cancer with chemotherapy drugs fluorouracil or capecitabine.

Hereditary orotic aciduria is caused by mutations in the uridine monophosphate synthetase (UMPS) gene, which impair the body's ability to synthesize adequate uridine. Uridine is essential for the conversion of orotic acid into pyrimidine nucleotide, a compound that is one of the building blocks of DNA and RNA. Uridine deficiency causes reduced pyrimidine nucleotide synthesis and urinary excretion of orotic acid.

Clinical evidence: Fifteen of 19 documented patients had abnormal hematologic parameters at presentation, including 15 with megaloblastic anemia, 8 with leukopenia, and at least 2 with neutropenia. Oral administration of exogenous sources of uridine was reported to significantly improve hematologic abnormalities within 2 to 3 weeks in almost all documented cases when administered in sufficient amounts.

Use of XURIDEN® (uridine triacetate) is supported by a single open-label clinical trial of uridine triacetate in 4 patients and a retrospective review of the clinical course of 18 patients with hereditary orotic aciduria who were treated with uridine beginning at ages 2 months to 12 years. There are no apparent differences in clinical response between adults and pediatric patients with hereditary orotic aciduria treated with uridine, however, data are limited.

Evidence strength: Strong for the clinical indication. Uridine triacetate (Xuriden®) is FDA-approved for hereditary orotic aciduria. The evidence base consists of case series and a small open-label trial, which reflects the extreme rarity of the disease rather than a deficiency in the quality of the therapeutic rationale.

5.2 Fluorouracil / Capecitabine Chemotherapy Overdose Rescue

Uridine triacetate (Vistogard®) is indicated for patients exhibiting early-onset, severe or life-threatening toxicity affecting the cardiac or CNS, and/or early onset, unusually severe adverse reactions (e.g., GI toxicity and/or neutropenia) within 96 hours following the end of fluorouracil or capecitabine administration. This is a separate FDA-approved indication for a pharmaceutical-grade uridine prodrug. Evidence strength for this indication is considered adequate for regulatory approval, though based on limited case series given the emergency nature of the treatment context.

5.3 HIV-Associated Mitochondrial Toxicity and Lipoatrophy

Background: Treatment of HIV infection with nucleoside analogue reverse transcriptase inhibitors (NRTIs) has been associated with numerous toxicities attributed to impaired mitochondrial function secondary to a reduction in the levels of mitochondrial DNA (mtDNA).

Mechanism: It has been demonstrated in cultured hepatocytes that uridine or its metabolites compete with tNRTIs at steps of mitochondrial pyrimidine import, degradation, or phosphorylation, thus countering mtDNA depletion due to tNRTIs and secondary impairment of the electron transport through the respiratory chain.

Clinical evidence: In a clinical study of 14 HIV-infected patients treated with stavudine or zidovudine, NucleomaxX® led to improved hepatic mitochondrial function as assessed by the ¹³C-methionine breath test. NucleomaxX® supplementation enhanced mitochondrial decarboxylation function reversibly but reproducibly in all patients.

A larger trial was subsequently conducted: A5229 was a phase II/III, randomized, double-blind, placebo-controlled study of uridine supplementation in the form of NucleomaxX® for the treatment of HIV-associated lipoatrophy. A parallel randomized 48-week study found that in HIV lipoatrophy, NucleomaxX® improved mtRNA, but worsened inflammation markers and fat mtDNA without changes in limb fat. Switching from a tNRTI to tenofovir (TDF) for 48 weeks increased limb fat and fat mtRNA.

A pilot trial enrolled 16 patients with lipoatrophy on stavudine-containing antiretroviral therapy, who received NucleomaxX® (36 g three times daily every other day for 16 weeks). Patients were then followed off-uridine for another 16 weeks. Highly active antiretroviral therapy remained unchanged during the trial. Fourteen patients completed the study.

Evidence strength: Moderate for mitochondrial function improvement; weak for reversal of lipoatrophy. Uridine supplementation shows consistent effects on mitochondrial biomarkers in cell culture and small human studies. However, the larger randomized trial (ACTG 5229) did not demonstrate significant improvement in limb fat, the primary clinical endpoint. Results are mixed and the use of first-generation thymidine analogues (stavudine, zidovudine) has itself declined substantially in clinical practice.

5.4 Neurological / Cognitive Function and Brain Membrane Synthesis

Pre-clinical evidence: A study examined the effects on cognitive behaviors of giving normal adult gerbils three compounds that interact to increase brain phosphatides, synaptic proteins, dendritic spines, and neurotransmitter release. Animals received supplemental uridine (as UMP; 0.5%) and choline (0.1%) via the diet, and DHA (300 mg/kg/day) by gavage, for 4 weeks. Giving all three compounds caused highly significant (P<0.001) increases in total brain phospholipids and in each major phosphatide. DHA plus choline improved performance on maze tests; coadministering UMP further enhanced these increases.

Largest increases in phospholipid (PL) levels and greatest enhancement in memory occur when all three circulating phosphatide precursors, uridine, DHA, and choline, are given concurrently.

Evidence strength for cognitive function: Preliminary; largely pre-clinical (animal and cell culture). As of available literature, rigorous large-scale randomized controlled trials examining uridine alone for cognitive enhancement in healthy humans are lacking.

5.5 Alzheimer's Disease (Multinutrient Context)

Background observation: Recent studies have noted lower uridine levels in the blood of patients with Alzheimer's disease (AD) dementia, suggesting that uridine may be associated with clinical progression in AD. This low level may be related to lower nutrient intake in AD or increased demand for uridine in the regenerative synaptic membrane. In observational data, subjects with AD had lower CSF uridine, plasma choline, and higher CSF homocysteine concentrations, whereas subjects with MCI had lower plasma and CSF uridine compared to controls (all P < .05).

Clinical trial (multinutrient): Uridine monophosphate is a component of Fortasyn® Connect, the active nutrient combination in Souvenaid® — a medical food designed for AD. Fortasyn Connect includes precursors (uridine monophosphate; choline; phospholipids; eicosapentaenoic acid; docosahexaenoic acid) and cofactors (vitamins E, C, B12, and B6; folic acid; selenium) for the formation of neuronal membranes. In a 24-week, double-masked clinical trial at 48 clinical centers, 527 participants taking AD medications [52% women, mean age 76.7 years] were randomized 1:1 to daily, 125-mL oral intake of Souvenaid® or an iso-caloric control. In patients with more advanced AD who were on stable AD medication, no significant add-on effect of the multinutritional intervention on the primary outcome ADAS-cog was observed.

The efficacy and safety of Souvenaid® has been assessed in a research programme spanning more than 20 years, including high-quality international clinical trials of more than 2,000 participants at varying stages of cognitive decline and impairment.

Evidence strength: Moderate for early/prodromal AD in the multinutrient context; weak for uridine alone. Uridine is always studied as part of a multicomponent formula in the AD context, making it impossible to attribute effects to uridine specifically. The S-Connect trial found no significant benefit on the primary cognitive outcome in mild-to-moderate AD on medication. Results in prodromal AD from the LipiDiDiet trial are more encouraging but still require further replication. Uridine's isolated contribution cannot be disentangled from these combination trials.

5.6 Mood Disorders / Bipolar Depression

Animal model evidence: Antidepressant-like effects of uridine and omega-3 fatty acids were reported in the forced swim test in rats, a preclinical model used in depression research, with effects potentiated by combined treatment.

Human clinical evidence: An open-label case series of seven depressed adolescents with bipolar disorder were treated with uridine for 6 weeks. Treatment response was measured with the Children's Depression Rating Scale-Revised and the Clinical Global Impressions scale. Uridine was associated with decreased depressive symptoms and was well tolerated by study participants. The authors concluded that further systematic studies of uridine are warranted.

The benefit associated with uridine was not associated with switches to mania, treatment-emergent suicidal behavior, or serious adverse events. No clinically significant laboratory abnormalities were associated with uridine in the study.

A subsequent randomized, double-blind, placebo-controlled trial was registered (NCT01805440): This is a randomized, double-blind, placebo-controlled study of the investigational drug uridine as a treatment for depressed adolescents with bipolar disorder ("bipolar depression"). The study includes a translational neuroimaging component: magnetic resonance spectroscopy (¹H-MRS) brain scans performed at baseline and repeated following 6 weeks of treatment with uridine or placebo.

Uridine is considered experimental because it has not been approved by the U.S. Food and Drug Administration (FDA) to treat bipolar depression in adolescents.

Evidence strength: Very preliminary. The only human evidence consists of a small (n=7) open-label uncontrolled case series. Randomized controlled trials in adolescents have been registered but peer-reviewed results are not yet widely published. Claims about uridine as an antidepressant in humans are not yet supported by adequately powered, controlled human trials.

5.7 Neurodegenerative Diseases: Parkinson's and Huntington's Disease

In addition to Alzheimer's disease, uridine has been shown neuroprotective for Parkinson's and Huntington's disease in animal models. Treatment with PN401 (a uridine prodrug) reduces the loss of dopamine neurons induced by MPTP, an inhibitor of mitochondrial complex I, in Parkinson's disease mouse models.

Evidence strength: Preclinical only (animal models). No human clinical trials in Parkinson's or Huntington's disease have been published as of available literature.

5.8 Sleep and Infant Neurodevelopment

One study found that adding tryptophan, adenosine, and uridine to an infant cereal fed at night to infants 8–16 months of age with pre-existing sleep disorders led to an improvement in sleep patterns. However, because this intervention combined multiple compounds, the independent contribution of uridine cannot be determined.

5.9 Metabolic Disease and Obesity

Uridine has an effect on body temperature and circadian rhythms, which can regulate the metabolic rate and the expression of metabolic genes. Abnormal levels of blood uridine have been found in people with diabetes and obesity, suggesting a link between uridine dysregulation and metabolic disorders.

Evidence strength: Observational and preliminary. Associations between dysregulated uridine levels and metabolic diseases have been noted, but interventional human evidence demonstrating benefit of uridine supplementation in these conditions is lacking as of available literature.

6. Body Systems and Health Areas Associated with Uridine

• Central nervous system: Synthesis of membrane phospholipids, dendritic spine formation, neurotransmitter support (acetylcholine, dopamine modulation), neuroprotection against metabolic and oxidative stress, antiepileptic effects in animal models.
• Hematological system: Correction of megaloblastic anemia, leukopenia, and neutropenia in hereditary orotic aciduria via pyrimidine replacement.
• Mitochondrial function: Counteraction of NRTI-induced mtDNA depletion; enhancement of mitochondrial bioenergetics in cell and animal models.
• Carbohydrate and energy metabolism: Role in galactose metabolism via UDP-glucose pathways; influence on glycogen synthesis and O-GlcNAcylation; associations with metabolic disorders including diabetes and obesity.
• Circadian regulation: Influence on circadian gene expression and metabolic rhythmicity.
• Immune and inflammatory systems: Uridine plays a pivotal role in various biological processes, including macromolecule synthesis, circadian rhythms, inflammatory response, antioxidant processes, and aging.

7. Dosage Forms and Reported Dosages

No universal recommended dietary allowance (RDA) or tolerable upper intake level (UL) exists for uridine in the context of healthy adults. The following dosages derive exclusively from published clinical research or official regulatory documents:

Hereditary Orotic Aciduria (Pharmaceutical)

• The recommended dose of XURIDEN® (uridine triacetate) is 60 mg/kg daily, which can be titrated to 120 mg/kg daily if needed (maximum of 8 g/day).
• The safety of XURIDEN® was assessed in 4 patients with hereditary orotic aciduria ranging in age from 3 to 19 years who received 60 mg/kg of XURIDEN® once daily for six weeks. All patients continued to receive XURIDEN® for at least 24 months at dosages of up to 120 mg/kg once daily. No adverse reactions were reported.

HIV-Associated Mitochondrial Toxicity / Lipoatrophy

• Sixteen patients received NucleomaxX® 36 g three times daily every other day for 16 weeks in the pilot lipoatrophy trial.
• One reported case used 3 sachets (36 g each) per day for 4 days.

Bipolar Depression (Investigational)

• Adolescent participants with bipolar disorder were treated with uridine 500 mg twice daily for six weeks in one open-label study.
• In the subsequent randomized controlled trial, subjects received uridine 500 mg twice daily by mouth for 6 weeks.

Reported Ranges Across Clinical Trials (Dietary Supplement Context)

• The uridine dosage in clinical trials varied from 1 g/day in depressed adolescents to 2 g/day in healthy adults. This amount can be split into two or three doses during the day.
• In adolescents, uridine was given for up to 6 weeks.

8. Safety Considerations and Interactions

General Tolerability

Doses of oral uridine or of uridine prodrugs are well tolerated in humans, with mild osmotic diarrhea being dose-limiting in excessive doses.

No adverse reactions were reported with XURIDEN® in the pivotal open-label trial in hereditary orotic aciduria patients. Currently, there are no reported drug interactions or known adverse reactions with Xuriden® treatment.

In the adolescent bipolar case series, uridine treatment was not associated with switches to mania, treatment-emergent suicidal behavior, serious adverse events, or clinically significant laboratory abnormalities.

Interactions with Antiretroviral Drugs

Phenotypic HIV-resistance assays and animal data do not indicate that uridine or its metabolites interfere with NRTIs at HIV reverse transcriptase. This is a pharmacologically important finding because it suggests that uridine supplementation does not compromise antiretroviral efficacy in the context for which it has been most studied.

Contraindication: Co-administration with Fluorouracil or Capecitabine (Non-emergency)

Uridine triacetate is not recommended for non-emergent treatment of adverse reactions associated with fluorouracil or capecitabine because it may diminish the efficacy of these drugs. This is a clinically important interaction: since uridine competes with fluorouracil metabolites, therapeutic use of uridine during active chemotherapy with these agents could theoretically reduce the antineoplastic effect.

Pregnancy and Lactation Data

There are no available data on XURIDEN® use in pregnant women to inform a drug-associated risk. When administered orally to pregnant rats during the period of organogenesis, uridine triacetate at doses similar to the maximum recommended human dose (MRHD) of 120 mg/kg per day was not teratogenic and did not produce adverse effects on embryo-fetal development. There are no data on the presence of uridine triacetate in human milk, the effect on the breastfed infant, or the effect on milk production.

Bioavailability and Form-Specific Considerations

Historically, the use of uridine as a therapeutic agent has been limited by poor bioavailability. The triacetyluridine (TAU) prodrug form significantly improves oral absorption. The rapid, dramatic rises in plasma uridine observed after administration of NucleomaxX® contrast with those seen with equimolar amounts of pure uridine, highlighting the potentially beneficial pharmacokinetics of this dietary supplement form. This distinction is relevant to dosing comparisons across studies, which often use different chemical forms.

Plasma Elevation by Other Factors

Plasma uridine is increased by muscular exercise, ethanol ingestion, fructose infusion, and xylitol infusion, which are well known to enhance adenine nucleotide degradation and lead to an increase in the plasma concentration of purine bases. These physiological interactions may be relevant when interpreting baseline uridine measurements in study populations.

References

• HandWiki — Chemistry: Uridine
• ScienceDirect Topics — Uridine (Overview)
• Biology Online Dictionary — Uridine
• Biology Online Dictionary — Uridine Monophosphate
• Biology Online Dictionary — Uridine Triphosphate
• PMC — The Role of Uridine in Health and Disease (2025)
• PMC / Frontiers in Physiology — Uridine and its role in metabolic diseases, tumors, and neurodegenerative diseases (Yang et al., 2024)
• PMC — Dietary uridine enhances the improvement in learning and memory produced by administering DHA to gerbils (Wurtman et al., 2008)
• PMC — Dietary supplementation with UMP increases acetylcholine level and release in striatum of aged rat
• PMC — Nutritional modifiers of aging brain function: Increasing the formation of brain synapses by administering uridine and other phosphatide precursors (Wurtman, 2011)
• PMC — Cytidine and Uridine Increase Striatal CDP-Choline Levels Without Decreasing Acetylcholine Synthesis or Release
• PMC — Open-Label Uridine for Treatment of Depressed Adolescents with Bipolar Disorder (Kondo et al., 2011)
• ClinicalTrials.gov — Uridine Adolescent Bipolar Depression Randomized Controlled Trial (NCT01805440)
• PMC — Enhanced Uridine Bioavailability Following Administration of a Triacetyluridine-Rich Nutritional Supplement
• PMC — Uridine supplementation in the treatment of HIV lipoatrophy: Results of ACTG 5229 (McComsey et al., 2010)
• PMC — Mitochondrial function, inflammation, fat and bone in HIV lipoatrophy: randomized study of uridine supplementation or switch to tenofovir
• PubMed — Uridine supplementation in HIV lipoatrophy: pilot trial on safety and effect on mitochondrial indices
• PubMed — Uridine supplementation enhances hepatic mitochondrial function in thymidine-analogue treated HIV-infected patients
• FDA — XURIDEN® (uridine triacetate) Full Prescribing Information (2019)
• PMC — The S-Connect study: results from a randomized, controlled trial of Souvenaid in mild-to-moderate Alzheimer's disease
• ScienceDirect — Stimulation of CDP-choline synthesis by uridine or cytidine in PC12 cells
• PMC — Uridine and its role in metabolic diseases, tumors, and neurodegenerative diseases (2024, full article)